Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2456-2463

  Sisley, Stephanie ^a,b   Gutierrez Aguilar, Ruth ^c   Scott, Michael ^d   D'Alessio, David A ^c   Sandoval, Darleen A ^c   Seeley, Randy J ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; LIRAGLUTIDE;

ANIMAL EXPERIMENT; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERA; WEIGHT REDUCTION;

ANIMALS; APPETITE DEPRESSANTS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; DIET, HIGH-FAT; EATING; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PERIPHERAL NERVES; RECEPTORS, GLUCAGON;

EID: 84902208322     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72434     Document Type: Article

References (40)

1. Sandoval D. CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav. 2008;94(5):670-674.
2. Buse JB, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124.
3. Niswender K, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15(1):42-54.
4. Lockie SH. The GLP-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. J Neuroendocrinol. 2013;25(7):597-604.
5. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152(8):3103-3112.
6. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci. 2011;31(10):3904-3913.
7. Tronche F, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23(1):99-103.
8. Scott MM, Williams KW, Rossi J, Lee CE, Elmquist JK. Leptin receptor expression in hindbrain GLP-1 neurons regulates food intake and energy balance in mice. J Clin Invest. 2011;121(6):2413-2421.
9. Bruning JC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289(5487):2122-2125.
10. Dubois NC, Hofmann D, Kaloulis K, Bishop JM, Trumpp A. Nestin-Cre transgenic mouse line Nes-Cre1 mediates highly efficient Cre/loxP mediated recombination in the nervous system, kidney, and somite-derived tissues. Genesis. 2006;44(8):355-360.
11. Dorisetty RK, Kiran SG, Umrani MR, Boindala S, Bhonde RR, Venkatesan V. Immuolocalization of nestin in pancreatic tissue of mice at different ages. World J Gastroenterol. 2008;14(46):7112-716.
12. Delacour A, Nepote V, Trumpp A, Herrera PL. Nestin expression in pancreatic exocrine cell lineages. Mech Dev. 2004;121(1):3-14.
13. Vahl TP, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology. 2007;148(10):4965-4973.
14. Pattyn A, Morin X, Cremer H, Goridis C, Brunet JF. Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis. Development. 1997;124(20):4065-4075.
15. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology. 2012;62(5-6):1916-1927.
16. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22(23):10470-10476.
17. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the longacting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50(11):2530-2539.
18. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes. 2008;57(8):2046-2054.
19. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes. 2009;58(12):2820-2827.
20. Scrocchi LA, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996;2(11):1254-1258.
21. Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ. Glucagon-like peptide-1 receptor knockout mice are protected from highfat diet-induced insulin resistance. Endocrinology. 2010;151(10):4678-4687.
22. Hunt JV, Washington MC, Sayegh AI. Exenatide and feeding: possible peripheral neuronal pathways. Peptides. 2012;33(2):285-290.
23. Hayes MR, et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagonlike-peptide-1. Am J Physiol Regul Integr Comp Physiol. 2011;301(5):R1479-R1485.
24. Zhang J, Ritter RC. Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms. Am J Physiol Regul Integr Comp Physiol. 2012;302(2):R264-R273.
25. Tatarkiewicz K, Sablan EJ, Polizzi CJ, Villescaz C, Parkes DG. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor [published online ahead of print: January 29, 2014]. Am J Physiol Regul Integr Comp Physiol. doi:10.1152/ajpregu.00495.2013.
26. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647-658.
27. Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
28. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, nondiabetic adults [published online ahead of print September 3, 2013]. Int J Obes (Lond). doi:10.1038/ijo.2013.162.
29. Tan TM, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131-1138.
30. Kim JG, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 2003;52(3):751-759.
31. Yamamoto H, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110(1):43-52.
32. Thompson DG, Wingate DL, Thomas M, Harrison D. Gastric emptying as a determinant of the oral glucose tolerance test. Gastroenterology. 1982;82(1):51-55.
33. Knauf C, et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology. 2008;149(10):4768-4777.
34. Wilson-Pérez HE, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes. 2013;62(7):2380-2385.
35. Belgardt BF, et al. Hypothalamic and pituitary c-Jun. N-terminal kinase 1 signaling coordinately regulates glucose metabolism. Proc Natl Acad Sci U S A. 2010;107(13):6028-6033.
36. Rossi J, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 2011;13(2):195-204.
37. Trumpp A, Depew MJ, Rubenstein JL, Bishop JM, Martin GR. Cre-mediated gene inactivation demonstrates that FGF8 is required for cell survival and patterning of the first branchial arch. Genes Dev. 1999;13(23):3136-3148.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25(4):402-408.
39. Ellacott KLJ, Morton GJ, Woods SC, Tso P, Schwartz MW. Assessment of feeding behavior in laboratory mice. Cell Metab. 2010;12(1):10-17.
40. McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH. NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. Am J Physiol Endocrinol Metab. 2009;297(4):E849-E855.